Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial -

Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial
Information type: Randomised controlled trials
Source: The Lancet Oncology
Specialities: Cancers
Summary
CT (n=1265) found that adding oxaliplatin to 5-FU-based neoadjuvant chemoradiotherapy (CT) and adjuvant CT significantly improved disease-free survival of patients with clinically staged cT3–4 or cN1–2 rectal cancer vs. former 5-FU-based combined modality regimen.
UKMi comment
A commentary notes that adding oxaliplatin preoperatively and postoperatively to the treatment schedule of patients with a primary rectal cancer considered to be locally advanced as defined in the trial (cT3–4, any N+) could result in a pronounced overtreatment, risking long-lasting neuropathy in many patients. Updated results from additional trials will add to the knowledge base and make estimations of the potential gains clearer.
Related links: Comment